{
  "headers": [],
  "notes": "6 3LL-Î”NRAS cells were carried out for orthotopic studies using 8-12 week old C57BL/6J mice. Mice were euthanised, with an overdose of pentobarbitone, when a humane endpoint of 15% weight loss was reached or any sign of JD has and has stock options and is co-founder of Achilles Therapeutics. TDdG is advisor to LAVA Therapeutics, GE Health, and Mendus, received research funding from Idera Pharmaceuticals, and holds stocks in LAVA Therapeutics. The other authors declare that they have no competing interests.",
  "caption": "acted as a consultant for AstraZeneca, Jubilant, Theras, Roche and Vividion and has funded research agreements with Bristol Myers Squibb, Revolution Medicines and AstraZeneca. CS acknowledges grant support from Pfizer, AstraZeneca, Bristol Myers Squibb,",
  "rows": [
    [{
      "colspan": 1,
      "content": "Roche-Ventana, Boehringer-Ingelheim, Archer Dx Inc (collaboration in minimal residual"
    }],
    [{
      "colspan": 1,
      "content": "disease sequencing technologies) and Ono Pharmaceutical, is an AstraZeneca Advisory Board"
    }],
    [{
      "colspan": 1,
      "content": "member and Chief Investigator for the MeRmaiD1 clinical trial, has consulted for Pfizer,"
    }],
    [{
      "colspan": 1,
      "content": "Novartis, GlaxoSmithKline, MSD, Bristol Myers Squibb, Celgene, AstraZeneca, Illumina,"
    }],
    [{
      "colspan": 1,
      "content": "Genentech, Roche-Ventana, GRAIL, Medicxi, Bicycle Therapeutics, and the Sarah Cannon"
    }],
    [{
      "colspan": 1,
      "content": "Research Institute, has stock options in Apogen Biotechnologies, Epic Bioscience, GRAIL,"
    }]
  ]
}
